Also found in: Medical.
Related to medoxomil: azilsartan medoxomil


A univalent organic group, C5H5O3, chiefly used in combination with olmesartan as a prodrug.

[me(thyl) + d(i)- + oxo- + alteration of m(eth)yl.]
Mentioned in ?
References in periodicals archive ?
- Cardio-cerebral medicine Olmesartan Medoxomil Tablet and respiratory medicine Fudosteine tablets have passed Consistency Evaluation.
Olmesartan medoxomil (OLME), CAS = 144689-63-4,1Himidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester, is a prodrug that is subjected to enzymatic hydrolysis, and its active product, olmesartan, is an angiotensin II receptor blocker (ARB) used in treatment and prophylaxis of hypertension.
Already before and during the pregnancy, she was treated with 5 mg olmesartan medoxomil, an angiotensin II receptor antagonist, because of grade 1 essential hypertension without evidence of end-organ damage.
Lupin Pharmaceuticals Inc., for one, this month introduced olmesartan medoxomil tablets, 5 mg, 20 mg and 40 mg.
M2 PHARMA-July 18, 2017-FDA approves Alembic Pharmaceuticals' ANDA for Olmesartan Medoxomil and Amlodipine tablets
Glenmark Pharmaceuticals has received final approval from the US health regulator for Amlodipine and Olmesartan Medoxomil tablets, used in the treatment of hypertension.
M2 EQUITYBITES-May 26, 2017-Glenmark Pharma gains US FDA approval for its blood pressure generic Olmesartan Medoxomil
Ali, "Design, formulation and optimization of novel soft nanocarriers for transdermal olmesartan medoxomil delivery: in vitro characterization and in vivo pharmacokinetic assessment," International Journal of Pharmaceutics, vol.
After 4 weeks, her antihypertensive medication (amlodipine/olmesartan medoxomil 10/20 mg) was discontinued and her blood pressure remained stable (Figure 2).
2 -- Ajanta Pharma Limited, announces today US FDA* approval and launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc.
(7) Amlodipine, chlorthalidone, and azilsartan medoxomil, all of which have long half-lives, are approximately 50% more potent than other antihypertensive agents.